Amyloid heart disease is under-recognized. Early detection and prompt initiation of therapy are critically important. With advances in imaging technology, the diagnosis or surveillance of cardiac ...

Several case reports and retrospective cohort studies have described a marginal benefit with the use of internal cardioverter defibrillators in patients with cardiac amyloidosis. Detection of ...

Background Cardiac amyloidosis (CA) is an underdiagnosed, progressive and lethal disease. Machine learning applied to common ...

Dr Mayowa Kolade, a consultant nuclear medicine specialist at the University College Hospital, Ibadan, in this interview with ...

Pfizer has awarded $80,000 to Rutgers Robert Wood Johnson Medical School (RWJMS) to fund an Amyloidosis Fellowship at Robert ...

The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 33,277 patients in 2024.

This is due to how AL amyloidosis affects vital organs, particularly the heart. AL amyloidosis may have a greater impact on the outlook for people with smoldering MM than symptomatic MM.

But these proteins have an impact on more than the heart. They travel to other places in the body, as well, she says. Amyloid buildup can affect the gastrointestinal system, the peripheral nervous ...

EMA’s human medicine committee recommends marketing approval for acoramidis for treatment of transthyretin amyloid cardiomyopathy: Berlin Monday, December 16, 2024, 13:00 Hrs [I ...